Diabetes Remote Care Management System

Diabetes Clinical Trial

— DRMS  

Official title:

Diabetes Remote Care Management System

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01354015
• Other study ID #: 1-Fonseca
• Status: Completed
• Phase: N/A
• First received: May 6, 2011
• Last updated: January 12, 2015
• Start date: May 2011
• Est. completion date: September 2014

Study information

• Verified date: January 2015
• Source: Tulane University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

DRMS is a system that communicates with patients via text message using cellphones, computers and other devices. It reminds patients about multiple health care and disease related issues such as to test their blood sugars and send the result back to the system via text message. The system will then decided based on automated algorithms whether to send another message advising patients on changing their medication etc.

This pilot will enroll 100 injectible insulin dependent patients with uncomplicated Type 1 and Type 2 diabetes mellitus, using insulin, who will be enrolled to participate in the pilot. Patients will be randomized 1:1 to either DRMS or standard care. The patients in the DRMS program will undergo interactions with the system using multiple communications channels including cell phones, IVR, email, web and SMS messaging. The goals of the interactive programs are the following:

1. Monitor and intervene to remind patients to fill their prescriptions

2. Monitor and track insulin unit consumption utilization and timing of that dosage

3. Monitor and intervene when the patient does not use or take their medications as prescribed.

4. Monitor and track insulin unit consumption and timing of that dosage

5. Ask the patient for their glucose levels and then provide customized information to the patients regarding how to modify their medication to achieve the desired glucose level

6. Deliver automated dose adjustment directions based on the providers instructions

7. Coordinate personalized educational programs and messages into the automated intervention programs

8. Provide feedback to the patients, including performance and reinforcement to both providers and to patients.

9. Provide feedback to providers on patients performance as well as exception based reporting

The System will manage interventions in an automated fashion. Providers will intervene on an exception basis and only when automated interventions have not worked or the protocol requires immediate action by the provider. For example, if the glucose exceeds certain danger levels, as defined by the provider, a requirement might be to call and notify the doctor immediately.

Description:

Primary Objective To determine the feasibility of using cell and phone technology to monitor, intervene and manage diabetes in patients using insulin.

Secondary Objectives:

1.To determine whether the DRMS system leads to improved glucose control (as measured by HgA1cHbA1c) during participation in the pilot

.2.To determine whether the DRMS system leads to improved management and adherence to insulin as well as other diabetic medications .3.To determine whether the DRMS system can be used as a cost effective solution for interventions across a broad segment (both demographic and economic groups) of the diabetes population.

This pilot will enroll 100 injectible insulin dependent patients with uncomplicated Type I1 and Type II2 diabetes mellitus, using insulin, who will be enrolled to participate in the pilot. Patients will be randomized 1:1 to either DRMS or standard care. It is anticipated that 150 patients will be screened in order to enroll 100 patients in the clinical trial. The patients in the DRMS program will undergo interactions with the system using multiple communications channels including cell phones, IVR, email, web and SMS messaging. The goals of the interactive programs are the following:

1. Monitor and intervene to remind patients to fill their prescriptions

2. Monitor and track insulin unit consumption utilization and timing of that dosage

3. Monitor and intervene when the patient does not use or take their medications as prescribed.

4. Monitor and track insulin unit consumption and timing of that dosage

5. Ask the patient for their glucose levels and then provide customized information to the patients regarding how to modify their medication to achieve the desired glucose level

6. Deliver automated titration directions based on the providers instructions

7. Coordinate personalized educational programs and messages into the automated intervention programs

8. Provide feedback to the patients, including performance and reinforcement to both providers and to patients.

9. Provide feedback to providers on patients performance as well as exception based reporting

The System will manage interventions in an automated fashion. Providers will intervene on an exception basis and only when automated interventions have not worked or the protocol requires immediate action by the provider. For example, if the glucose exceeds certain danger levels, as defined by the provider, a requirement might be to call and notify the doctor immediately.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 98
• Est. completion date: September 2014
• Est. primary completion date: September 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. 18 years of age or older.

2. Able to read and understand the ICF and provide written consent.

3. Diagnosis of Type 1 or Type 2 diabetes. If Type 1 diabetes, requirement that they be on insulin and if Type 2 diabetes, requirement that they be on r insulin.

4. Recent HbA1c blood test (within the last 30 days).

5. An HbA1c reading of 7.5% - 9.0%.

6. Patient must own or have access to cell phone on a daily basis throughout the study period, and optionally can have a conventional phone or access to the Internet.

7. Patient possesses a blood sugar monitor and has access to supplies.

8. Patient is felt to be able to be compliant with the study.

9. Patient has no plans to move over the 6 month period of the study.

Exclusion Criteria:

1. Have active cancer other than basal cell carcinoma or cervical or breast cancer in situ.

2. In the opinion of the investigator are not suitable for entry into the study.

3. History of any psychiatric or neurologic condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide informed consent

4. Pregnant or breast-feeding females.

5. History (within last 6 months) of significant cardiovascular disease unless the disease is well-controlled. Significant cardiac diseases includes second/third degree heart block; clinically significant ischemic heart disease; QTcF interval > 450 msec at screening; poorly controlled hypertension; congestive heart failure of New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea) or uncontrolled cardiac arrhythmias.

6. History of cerebrovascular accident (CVA) within 6 months prior to randomization or that resulted in ongoing neurologic instability.

7. Active infection or serious underlying medical condition (including any type of active seizure disorder within 12 months prior to randomization) that would impair the ability of the patient to participate in the trial.

8. Hypoglycemia Unawareness

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes

Intervention

Device:
• DRMS
USE OF TEXT MESSAGING SYSTEM

Locations

Country	Name	City	State
United States	Tulane University	New Orleans	Louisiana

Sponsors (2)

Lead Sponsor	Collaborator
Tulane University School of Medicine	Eli Lilly and Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in HbA1c	change in A1c from baseline in intervention and control groups	6 months	No
Secondary	Fall in HbA1c Over 3 Months	Fall in HbA1c	3 months	No